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Effective local hyperthermia for cancer requires selective elevation of intratumoral 
temperature without overheating of surrounding normal tissues.  Temperature elevation 
depends upon the balance between absorbed power density, which heats the treated tissue, and 
blood perfusion, which cools it. Selectivity can be achieved by manipulations of vascular 
physiology to increase blood cooling of normal tissues or to decrease blood cooling of tumor 
tissue.  Creation of a favorable normal-to-tumor blood flow ratio is possible because the small 
blood vessels supplying most tumors are structurally and functionally different from the 
microvasculature of normal tissues. Normal arterioles dilate in heated tissues to raise local 
blood flow; whereas tumor vessels generally do not.  This difference in vascular 
responsiveness provides a target for selective drug action that can be exploited to enhance 
local heat therapy of tumors.  Vasodilator drugs, in particular, have profound effects upon the 
distribution of blood flow between tumor and adjacent normal tissues.  Dilation of normal 
arterioles improves blood flow in normal tissues and may also shunt blood away from the 
tumors.  These effects have been demonstrated in small animals, in large animals, and in 
humans to varying degrees.  Further clinical exploitation of the microvascular differences 
between tumors and adjacent normal tissues may lead to improved effectiveness of 
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For the purpose of the present review it is useful to consider that the therapist's goal during 
local heat therapy for cancer is to elevate the temperature of the entire tumor mass above 
some cytotoxic threshold, such as 43 °C, while maintaining all surrounding normal tissue at a 
safe, non-lethal temperature.  Ideally the temperature distribution within the tumor would be 
uniform, approaching a perfect step-function that rises abruptly to therapeutic levels at the 
tumor edge. Uniform intratumoral temperatures not only ensure an absence of cold spots 
within the tumor that may lead to treatment failures, but also may reduce the incidence of hot 
spots that have been associated with an increased incidence of complications [23, 24].  Of 
course, because of continual conductive heat transfer from warmer to cooler tissues, a perfect 
step-function in temperature distribution can never be achieved, but only approximated.  
Moreover, for some malignancies the tumor "edge" may not be sharply defined, owing to 
irregular microscopic invasion.  Nevertheless, progress in both technological and biological 
aspects of hyperthermia holds promise that markedly improved selectivity of intratumoral 
temperature elevation is indeed possible. 
 
Much engineering effort has been devoted to improved means of focusing energy upon tumor 
tissue, an obvious strategy for improving selectivity.  This approach requires that the therapist 
(1) know exactly where the tumor is and (2) have the technological means of administering 
power to it, but not to surrounding normal tissues.  These constraints are especially vexatious 
if the tumor is deep lying.  The potentials and limitations of approaches involving ultrasound 
or interstitial antennas for focusing absorbed power in tumor, but not in normal tissue, are 
discussed elsewhere [58, 75, 76]. 
 
This review focuses on biological means for enhancing the selectivity of local heat treatment 
by improving the partitioning of blood flow between tumor and surrounding normal tissue, so 
that the normal tissue is cooled relatively more, and the tumor is cooled relatively less. This 
state of affairs permits greater power input to the tumor bearing region and, in turn, higher 
intratumoral temperatures.  The concepts presented are applicable to a wide variety of 
technologies for power application, including ultrasound, radiofrequency, or microwave 
energy, delivered by either surface or interstitial applicators. 
 
Blood flow as a principal determinant of steady-state temperature 
 
Given that power input to a treated tumor is focused upon the neoplastic tissue as much as is 
clinically and technologically feasible, the major controllable determinant of temperature 
profiles in and around larger tumor masses is the distribution of blood flow.  During local heat 
therapy, as opposed to whole-body hyperthermia, core body temperature remains close to 
normal, and so the circulation of blood tends to cool the heated region.  Accordingly, 
selectivity of local temperature elevations in solid tumors in vivo is related to differences in 
vascularization and blood flow between tumor tissues and normal tissues. Tumors possessing 
a high blood flow rates are difficult to heat, and tumors with little blood perfusion are easy to 
heat. 
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This principle is well demonstrated by computer solutions to the bio-heat transfer equation, 
which can be readily solved to describe temperature distributions in and around spherical or 
slab-like tumor models as a function of blood flow [4-6, 8, 21].  The bio-heat equation 
describes conductive heat transfer, as occurs in non-perfused solids, and also includes a blood 
perfusion term, based upon the assumption that heat loss from tissue into flowing capillary 
blood is proportional to capillary perfusion rate (ml blood/min/gram tissue) and the difference 
between tissue temperature and incoming arterial blood temperature.  Heat transfer in or near 
large vessels is not modeled, but in tissue far from so-called thermally significant, larger 
vessels, the bio-heat equation model has been found to be reasonably valid [17], especially for 
predicting temperature distributions on larger scales of several centimeters or more, which are 
relevant to clinical hyperthermia [4, 8, 17, 21, 46]. 
 
The bio-heat transfer equation describes the balance between the rate at which heat energy is 
deposited in the tissue by the external energy source and the countervailing rate at which heat 
leaves the tissue as a result of thermal diffusion (conduction) and perfusion of the tissue with 
blood. In any specific numerical solution one must specify the tumor dimensions and the 
distributions of blood flow and applied power in and around the tumor. Considering published 
work describing tumor blood flow [10, 36, 63, 71], one can begin, for example, by simulating 
deep lying, spherical tumors under the following specific conditions: Tumor radii 5, 10, 20, or 
40 mm; power deposition uniform in intensity and extending from the center of the tumor to 
twice the radius of the tumor; tumor blood flow 0.2 ml/min/g; normal tissue blood flow 
ranging from 0.2 to 0.8 ml/min/g. It is also revealing to adjust power input--as one would 
hope to do in practice-- to keep the normal tissue at the edge of the tumor a "safe" 
temperature, for example 42 °C. 
 
Figures 1 A--D show temperature profiles computed for such circumstances.  The solid curves 
represent basal conditions in which blood flow in surrounding normal tissue is the same as 
that in the tumor (0.20 ml/min/g).  The dashed and dotted lines represent two increased levels 
of normal tissue perfusion (0.40 or 0.80 ml/min/g), with tumor perfusion remaining 
unchanged. Note that central tumor temperatures approaching 10 °C greater than core 
temperature and over 5 °C greater than surrounding normal tissue can be achieved when blood 
flow is greater in normal tissue than in tumor.  The explanation of this effect is that with better 
blood cooling of normal tissue, the therapist can apply much greater power to the entire 
treated region before tumor edge temperature reaches the limit of 42 °C.  As a result, tumor 
temperatures rise to higher steady state levels. 
 








     
 
Figure 1. Temperature profiles computed from the bio-heat equation for 5, 10, 20, and 
40 mm radius tumors (A--D) surrounded by homogeneous normal tissue. r0 is the 
tumor radius; rRx is the treatment radius for applied power.  Tumor perfusion is 
always 0.20 ml/min/g.  In A power input was 0.17412, 0.22622, and 0.31102 W/ml for 
blood flows of 0.20, 0.40, and 0.80 ml/min/g in surrounding normal tissue.  In B power 
input was 0.09564, 0.13564, and 0.20188 W/ml for blood flows of 0.20, 0.40, and 0.80 
ml/min/g in surrounding normal tissue.  In C power input was 0.07358, 0.10857, and 
0.16035 W/ml for blood flows of 0.20, 0.40, and 0.80 ml/min/g in surrounding normal 
tissue.  In D power input was 0.06981, 0.10027, and 0.14062 W/ml for blood flows of 
0.20, 0.40, and 0.80 ml/min/g in surrounding normal tissue. 
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The effect of the tumor / normal blood flow ratio is similar for other plausible combinations of 
reduced tumor flow or enhanced normal tissue flow. Table 1 presents predicted center 
temperatures and temperature gradients (change in temperature/change in radial distance from 
tumor center) at the edges of the spherical tumor models for various flow conditions.  
Selectivity is achieved whenever tumor flow is relatively low compared to flow in normal 
tissues. It is not necessary for the absolute value of tumor blood flow to be near zero, but 
rather for the ratio of tumor to normal tissue flow to be low.  Under such conditions there can 
be adequate power input to the treated region to achieve therapeutic intratumoral temperatures 
without excessive temperature elevation in normal tissues.  Obversely, if the level of tumor 
perfusion cannot be forced below that of surrounding normal tissue, selective elevation of 
tumor temperature is impossible without a high degree of power focusing. 
 
 
Table 1. Calculated tumor center temperatures for 




*Power adjusted to maintain tumor edge at 42 °C.  Data from Babbs et al., 1982. 
 
 
Spatial profile of perfusion 
 
The models presented in Figure 1 are, of course, highly simplified, particularly in assuming a 
uniform distribution of perfusion within the tumor, changing abruptly only at the tumor edge 
to assume another uniform value in normal tissue.  In actuality, of course, the distribution of 
perfusion is more complex.  A number of authors have described a radial distribution of tumor 
blood flow, in which a poorly perfused core is surrounded by a hyperperfused outer shell [26, 
28, 29, 38, 44]. The existence of a hyperperfused outer shell has been documented in at least 
some tumor types [28, 31, 44] and may be evident as a hypervascularized surface of many 
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solid tumors at surgery. Contrary, perhaps to intuition, the presence of a hyperperfused outer 
shell may actually improve the ability to selectively heat a tumor core under certain 
conditions. It is possible to demonstrate in simulations similar to those in Figure 1 that if 
tumor edge perfusion is twice normal tissue perfusion and 10 times tumor core perfusion, the 
entire tumor volume can still be maintained at greater than a target level (42 °C), if power 
input is adjusted to maintain the tumor edge at this target value [4]. Greater perfusion at the 
tumor edge does not necessarily prevent selective tumor heating. Indeed, moderately 
increased flow in the tumor shell permits greater power input to the tumor core and higher 
overall intratumoral temperatures [4], provided technology exists to maintain the edge at the 
desired minimum level. 
 
This effect is demonstrated in Figure 2, in which perfusion and computer generated steady-
state temperature profiles in a 20 mm radius tumor model with an underperfused core and a 
hyperperfused outer shell are presented.  Curves A and B represent two possible non-uniform 
distributions of tumor blood flow. The presence of a relatively well perfused tumor shell still 
permits greater power input to the tumor core and higher overall tumor temperatures, as long 
as power is adjusted to maintain the tumor edge at 42 °C. Of course, adequately precise 
adjustment of applied power may provide substantial practical difficulties for present 
technology.  However, in principle the existence of a hyperperfused outer shell does not 
necessarily obviate selective elevation of tumor temperature. 
 





Figure 2. Perfusion and steady-state temperature profiles during local heat therapy in 
two representations of a 20 mm radius tumor model with an underperfused core and a 
hyperperfused outer shell.  Power was adjusted to maintain tumor edge temperature at 
42°C. 
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Multiplication of perfusion effects by systemic blood cooling 
 
The full potential of blood flow differences enhancing the selectivity of tumor heating is 
nicely demonstrated by the limiting case in which tumor blood flow is zero and, in addition, 
the arterial blood temperature is reduced.  With the combination of local hyperthermia and 
systemic hypothermia [6, 62], blood cooling multiplies perfusion related temperature 
differences between tumor tissue and normal tissue during local heating. This phenomenon is 
predicted by the bio-heat equation, in which the perfusion term is represented by the product 
of the local blood flow, , and the prevailing difference between tissue temperature, T, and 
arterial blood temperature, Ta, [46], namely, heat loss from blood flow = (TTa). 
 
James Oleson, the author, and their coworkers have examined this interesting limiting case 
using autotransplanted sections of spleen with known zero perfusion as tumor models [6, 62].  
The objective was to determine if systemic blood cooling (in conjunction with vasodilators to 
enhance normal tissue flow) would permit lethal temperature elevations in a tumor model, 
sufficient to destroy a neoplasm in a single treatment session, while safe temperatures were all 
the while maintained in surrounding normal tissue. Temperature differences between a non-
perfused, auto-transplanted spleen implant and underlying normal muscle were recorded 
during local microwave therapy in anesthetized dogs, pretreated with the vasodilator, 
hydralazine, to maximize muscle blood flow. 
 
Figure 3 shows mean temperature-time curves for two sites about 0.5 cm from the 
tumor-normal muscle interface in 8 animals.  Much higher steady-state temperature 
differences between phantom tumor and underlying normal tissue were obtained after the 
vasodilator hydralazine (0.5 mg/kg, i.v.) was given and arterial blood temperature reduced to 
29 °C by packing the animal in ice (Figure 3 B) than were obtained before vasodilation and 
blood cooling (Figure 3 A).  The temperature differences between tumor and muscle averaged 
5.4 °C for normothermic vs. 19.8 °C for hypothermic conditions.  The corresponding 
temperature gradients (temperature difference / probe separation) were 4.9 ± 2.3 °C/cm for 
normothermia vs.  18.9 ± 5.6 °C/cm for hypothermia.  This effect, which is demonstrable in 
deeply seated as well as superficial tumor models [62], demonstrates the potential 
enhancement of selectivity that is possible when parameters are optimized to achieve maximal 
differential blood cooling of normal vs. tumor tissue. 
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Figure 3. Mean temperature-time curves(± 1 S.D.) for 8 animals during local heat 
treatment of spleen implants with systemic hypothermia. (A) during systemic 
normothermia (39 °C) and (B) during systemic hypothermia (30 °C).  Squares 
represent temperatures in tumor; circles represent temperatures in underlying muscle.  
Data from Babbs et al., 1985. 
 
 
Anatomic substrate for differential perfusion 
 
With this theoretical background, the question arises as to whether such dramatic perfusion 
and temperature differences between spontaneous, naturally occurring tumors and 
surrounding normal tissues are possible in vivo.  Certainly, a high degree of differential 
perfusion would hardly be expected if tumor vessels and normal vessels were essentially the 
same in their distribution, structure, and function.  However, a significant body of literature 
suggests that tumor vessels are substantially different from normal vessels in a variety of 
aspects, including their origin, construction, distribution, and responsiveness to hormones and 
drugs.  These fundamental differences have been extensively reviewed by Peterson [63] and 
by Reinhold and Endrich [65].  They provide significant opportunities for selective antitumor 
therapy, especially involving local hyperthermia. 
 
In brief, the classical histologic difference between the microcirculation of solid tumors and 
that of normal tissues is the abundance of sinusoidal capillary beds in tumor tissue.  These 
capillary sinusoids are broader, longer, and in some cases may be separated by larger 
intercapillary distances than normal capillaries [26, 35, 38, 44, 45, 77, 80].  The vessels 
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penetrate neoplastic tissue in response to a chemical messengers liberated by tumor cells [31].  
These tumor angiogenesis factors appear to stimulate the growth of such capillaries but not to 
stimulate the development of capillary sprouts into well differentiated, larger caliber 
arterioles.  Consequently, the density of arteries and arterioles in tumor tissues is abnormally 
small in relation to the venous vasculature [29, 35, 45]. 
 
A key concept at this juncture is the paucity to smooth muscle in tumor vasculature.  
Normally, the walls of blood vessels have three fundamental layers: an inner lining of 
endothelial cells, which is one cell layer thick, a middle layer of smooth muscle cells, which 
can be one or many cells thick, and in larger vessels an outer sheath of fibrous connective 
tissue, which is usually thinner than the middle layer.  These three layers are known 
respectively as the tunica intima, tunica media, and tunica adventitia. It is the smooth muscle 
in the tunica media of microscopic arteries that is responsible for the regulation of blood flow 
to tissues in response to hormones, drugs, and physical stimuli such as heat [41]. Tumor 
vessels that have been studied in this regard appear remarkably devoid of smooth muscle.  
The tunica media is simply not there. 
 
The photomicrograph in Figure 4 illustrates this essential difference in vascular architecture.  
The normal arteriole "A" within skeletal muscle tissue has significant wall thickness 
comprised of vascular smooth muscle.  The wall of the tumor vessel "B", of approximately 
the same external diameter, is comprised of only a single layer of endothelium.  No smooth 





Figure 4. Photomicrograph of normal and tumor vessels of comparable diameter.  A 
normal arteriole. B tumor vessel. 
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One study by Chan and coworkers [14] quantified vessel wall thicknesses in transplanted rat 
hepatomas, compared to those in normal tissues.  Thin-walled construction was typical of 
tumor vessels as shown by the histograms in Figure 5. Here vessels of two transplanted tumor 
types and of normal stomach and kidney are sorted according to wall thickness.  Note the log 
scale of the vertical axis. The density of tumor vessels with wall thickness in the range of 5-20 
microns (arterioles) is roughly 4 to 40 fold less in the two tumor types studied than in normal 
stomach and kidney.  This paucity of arterioles provides the anatomic substrate for the relative 





Figure 5. Histograms of the distributions of vessel wall thickness (in microns) in tumor 
vs. normal tissues in rats. There are more vessels and thicker walled vessels in normal 
than in tumor tissues.  These thicker walled vessels (5 to 20 microns in wall thickness) 
are identifiable as arterioles by standard light microscopic criteria. The paucity of 
arterioles in tumor tissue explains the lack of responsiveness of tumor vasculature to 
heat and to vasoactive drugs. Data from Chan et al., 1983. 
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A well known clinical demonstration of the microvascular differences between tumor and 
normal tissues has come to be known as Abrams sign. Over two decades ago Abrams 
described the use of intra-arterial epinephrine, a vasoconstrictor in the doses he used, to 
enhance angiographic contrast of renal tumors [1, 2]. He found that during renal 
arteriography, the opacification of the tumor vascular bed was greatly increased after 
epinephrine injection, while vessels to the surrounding normal renal parenchyma showed little 
evidence of filling.  Subsequent pathologic study showed "large thin-walled vessels within the 
tumor lacking in muscular tissue compared with normal vessels".  These observations are 
easily understood with reference to the parallel circuit analogy depicted in Figure 6; selective 
constriction of normal vessels tends to shunt blood flow away from normal kidney and into 
the tumor, improving angiographic contrast.  Subsequently, this technique has become a 




Figure 6. Parallel circuit analogy of tumor and normal microvasculature, an 
electrical analog to predict changes in tumor and normal tissue blood flow.  Rs = 
variable resistance in major arteries which later branch into the different organs and 
tumor.  R1 = resistance of normal organs. R2 = resistance of tumor vessels.  Normal 
arterioles are represented by a variable resistance (arrow) able to change in response 
to physiologic stimuli; tumor vessels are represented as a fixed resistance. 
 
In contradistinction to these effects of a vasoconstrictor, Jonsson and associates [48] studied 
the effects of intra-arterial prostaglandin E1, a potent vasodilator, as an adjuvant to 
angiography of tumors of the extremities in 10 patients.  Except in one case, involving a 
hemangioma, the arteriographic visualization of tumor vessels and delineation of the extent of 
disease were worse after the use of prostaglandin E1, while visualization of small normal 
muscular arteries improved.  Evidently, prostaglandin increased blood flow in normal tissues 
relative to the tumor. In similar studies Ekelund, Laurin, and Lunderquist compared the use of 
the vasoconstrictor, angiotensin, and the vasodilator, tolazoline, in the pharmacoangiography 
of bone and soft tissue tumors in 18 patients [27]. Angiotensin improved tumor visualization 
in 9/18 cases and reduced it in none.  Tolazoline improved tumor visualization in one case and 
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reduced it in six. They concluded that since the walls of newly formed vessels of such tumors 
are made up of endothelial cells and lack contractile elements [56, 57] and that 
vasoconstrictors provided the most diagnostic information (by forcing more blood into the 
tumor).  In contrast, during pharmacoangiography with the vasodilator, tolazoline, tumor 
vessels were often "drowned" within the normal vasculature.  The challenge of fine-tuning the 
dose of vasoactive drug to produce the maximal desired effect upon the tumor / normal tissue 
perfusion ratio, however, was suggested by their finding that the optimal dose levels for 
angiotensin were less for tumors in the kidney than for those in the extremities. 
 
Intratumoral vascular function 
 
These clinical phenomena, described in the radiologic literature, are congruent with reports of 
animal studies describing tumor blood vessels as sinusoidal capillary beds lacking in smooth 
muscle [26, 35, 38, 60, 74, 77] and exhibiting little vasomotion [33].  The lack of functionality 
of tumor vessels is of direct relevance to hyperthermia.  Song and coworkers have shown in a 
variety of studies with transplantable tumors in the rat that normal tissues such as skin and 
skeletal muscle increase perfusion in response to 43 °C hyperthermia by as much as six fold, 
whereas tumor flow remains essentially constant, increasing no more than two fold [71]. 
 
The failure of tumor flow to increase during hyperthermia probably means that tumor tissue is 
far less able to withstand heat stress than adjacent normal tissues--even if the temperature 
differential is modest or even non-existent.  Heat induced elevation of metabolism in tumor 
tissue without elevation of blood flow is certain to reduce local oxygen tension in the tumor, 
causing a downward shift of the cell-survival versus temperature curve [40]. Since it is well 
known that hypoxic and acidotic cells tolerate hyperthermia poorly, the differential vascular 
function of tumors just reviewed may explain the selectivity of heat therapy as currently 
practiced.  The now classic studies of Song and coworkers showing that solid tumor masses in 
vivo appear even more heat sensitive than cells from the same tumor line grown in vitro [52, 
72] appear to support this concept—that there are metabolic as well as thermal consequences 
of the abnormal structure and function of tumor microvasculature [22, 32, 35, 52, 72]. 
 
Additionally, the abnormal tumor vessels may be more susceptible to heat induced vascular 
thrombosis than normal vessels.  Dudar and Jain [25] have studied microvessels of rabbit 
VX2 carcinoma, as compared to normal, mature granulation tissues, grown in a transparent 
ear chamber. The chamber was observed microscopically during controlled, water jacket 
heating at 40-52 °C for 1 hour. These investigators found that blood flow in both tissues 
increased as a function of temperature and then decreased, indicating heat induced vascular 
stasis. However, the changes in tumor vessels were more profound.  Not only were the 
absolute flow and maximal increase in flow less in the tumor vessels, but also the temperature 
at which vascular stasis occurred was lower: 43 °C in tumor vessels vs. 46 °C in normal 
vessels, results similar to those from Song's laboratory [59].  Subsequent experiments by 
Ward-Hartley and Jain demonstrated that stimuli as innocuous as glucose injection can 
diminish red cell velocity selectively in tumor vessels by as much as 90 percent, perhaps by 
inducing local lactic acidosis [79], which increases red cell rigidity and the tendency of red 
cells to log-jam in tortuous tumor vessels.  Thus, in yet another aspect, it is evident that tumor 
microvasculature is ill suited to withstand the stresses imposed during hyperthermia. 
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Effects of vasoactive drugs 
 
If heat stress itself is a selective vasodilator for normal tissues that renders tumors relatively 
hypoxic, acidotic, and easy-to-heat; is there anything to be gained by use of drugs that are 
known, potent vasodilators?  The answer appears to be "yes", in view of several series of 
experiments performed by Chan and coworkers.  These investigators used the tracer 
microsphere technique to study the effects of vasodilators on the distribution of perfusion 
between tumor and normal tissues.  The use of microspheres to measure tumor blood flow is 
reasonably well established [7, 13, 66, 73].  Table 2 shows the effects of a vasodilator 
(hydralazine) and a vasoconstrictor (phenylephrine) on blood flow to normal tissues and to 
subcutaneous nodules of two types of transplantable tumor in rats [14]. Regional blood flow 
was measured using radioactive microspheres at the time of maximal blood pressure response 
to the drug. The vasodilator did not alter tumor blood flow, and the vasoconstrictor decreased 
flow in one of the tumor types.  In contrast, over-all normal tissue flow, indicated by cardiac 
output, was depressed by the vasoconstrictor and enhanced by the vasodilator. 
 
 
Table 2. Blood flow in normal and transplanted tumors of rats after treatment with a 





*Data from Chan et al., 1983. 
 
# Cardiac output 
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The studies of Chaplin and Acker [15] using C57 Black mice bearing Lewis lung tumors 
revealed a similar effect. These investigators found that hydralazine alone reduced the fraction 
of surviving tumor cells cultured from treated tumors, compared to untreated tumors, by 
approximately half. When hydralazine was combined with the hypoxic cell cytotoxin, RSU 
1069, the surviving fraction of tumor cells fell three orders of magnitude from 1/10 to 
1/10,000.  Whole tumor growth, measured as tumor volume, was also retarded by this 
combination therapy, which the authors concluded worked because of the ability of 
hydralazine to cause selective decreases in tumor blood flow and oxygenation. 
 
The overall effects of vasoactive drugs on the distribution of blood flow can be predicted by 
using the electrical analogy in Figure 6. The heart is represented as a pump that provides 
blood to different parts of the body, depending on the local peripheral vascular resistance.  A 
variable series resistor, Rs, represents the major arteries which later branch into the different 
organs and the tumor.  In essence, normal and tumor vascular beds are shown connected in 
parallel.  The normal tissues or organs, nourished by the healthy vessels capable of responding 
to vasoactive drugs, are represented by the variable resistor R1. The tumor tissues, nourished 
by vessels lacking smooth muscle, are represented by the fixed resistor, R2. When hydralazine 
is infused into the circulation, for example, it will be distributed throughout the body and 
dilate muscular arterioles.  As a result, resistance in these vessels (R1) will decrease causing 
more blood to flow through them. Cardiovascular reflexes tend to maintain mean aortic blood 
pressure by increasing heart rate and cardiac output.  Under these conditions normal tissue 
blood flow increases by as much as four fold [78].  Since the tumor vessels cannot respond to 
vasodilator drugs, the increase in tumor flow is small compared to that in normal tissues.  
Furthermore, if normal and tumor vessels originate from the same arterial branch, dilation of 
the normal vascular beds may shunt blood away from tumor tissue, actually reducing tumor 
blood flow (the so-called vascular steal phenomenon).  Conversely, if a vasoconstrictor is 
infused, normal tissue flow will decrease, arterial pressure will increase, forcing more blood 
through the tumor (Abrams sign). 
 
Animal data are consistent with this general hypothesis.  Knapp and coworkers [53], studying 
the Waker 256 tumor and the Yoshida sarcoma in rats, demonstrated selective reduction of 
blood flow in tumor transplants in response to the vasodilator, nisoldipine, a calcium entry 
blocker.  Nisoldipine decreased tumor perfusion by 63 percent, while increasing perfusion of 
normal muscle by 80 percent, as measured by the xenon washout technique.  They concluded 
that the result is probably a "steal" phenomenon, the deviation of the flow from the tumor to 
the host tissue by dilation of the resistance-determining blood vessels in non-tumor tissue. 
 
Mattsson, Lilja, and Peterson [60] used the xenon clearance method to study the influence of 
vasoactive drugs on blood flow to normal subcutaneous tissue and transplanted fibrosarcomas 
in rats.  They injected 0.02 ml volumes of xenon solution containing either the vasoconstrictor 
noradrenalin, or the direct acting vasodilator, papaverine.  After injection of noradrenaline, 
subcutaneous tissues showed a greater absolute and relative decrease in blood flow than did 
tumor tissue.  Conversely, the vasodilator papaverine, which acts directly on vascular smooth 
muscle, caused no change in tumor blood flow, compared to saline treated controls, but a 
roughly 40 percent increase in flow to subcutaneous tissue flow.  These results suggest that 
tumor vessels are relatively less reactive to vasoactive drugs than are normal vessels. 
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As early as 1962 Carter, Grigson, and Watkinson [11] reported that inhalation of amyl nitrite, 
a pharmacologic analog of nitroglycerin and a potent vasodilator, always lowered tumor 
oxygen tension in rodent models and produced a more rapid and marked reduction in oxygen 
tension of tumor than in that of muscle and bone marrow.  They went on to study the actions 
of 5-hydroxytryptamine (5 HT) in the Walker 256 tumor and Jensen sarcoma in rats and also 
spontaneous mammary carcinomas in mice.  5 HT is a radioprotector, being a scavenger of 
free radicals, but it is also a potent vasoactive agent, capable of causing either 
vasoconstriction or vasodilation, the latter especially in skeletal muscle [34].  In the rodent 
tumor models 5 HT produced a fall in blood pressure, indicating overall vasodilation of 
normal tissues.  At the same time 5 HT (5 mg/kg, i.p.) caused a prompt and marked decline in 
tumor oxygen tension.  Oxygen tension in normal muscle and spleen remained unchanged or 
fell less rapidly than tumor oxygen tension.  Even more remarkable was the abolition by 5 HT 
of the response of tumor oxygen tension to oxygen gas inhalation, suggesting a considerable 
degree of circulatory stasis in the tumor. 
 
In a follow-on study these same investigators found that 5 HT decreased apparent tumor 
perfusion after local heating, measured by a thermal washout technique [12]. They concluded 
that tumor circulation is already near its maximum, which nonetheless provides near 
minimum nutrition for the tumor.  In turn, vasodilatory drugs can do little but to steal blood 
away from the tumor and thereby lower tumor oxygen tension.  Knapp and coworkers [53] 
later found the same effects. 
 
In another investigation of 5 HT, Shrivastav, Joines, and Jirtle at Duke [70] studied the effect 
of the drug on blood flow to rat SMT-2A mammary adenocarcinoma during localized 
microwave heating.  They measured tissue blood flow with radioactive microspheres and 
found that tumor blood flow was halved, while flow to surrounding skeletal muscle remained 
unchanged.  This effect was accompanied by improvement in the temperature differential 
between tumor and surrounding normal tissue.  The failure of normal flow to increase in these 
animals is still consistent with the simple parallel circuit analogy, if it is assumed that the drug 
also lowered arterial blood pressure, as well as causing skeletal muscle vasodilation.  
 
The simple parallel circuit analogy, however, is inadequate to explain all the data.  In studies 
with catecholamines, Gullino and Gratham measured blood flow in kidneys and ovaries of 
rats and mice almost totally replaced by tumor.  They found a decrease in blood flow to 
implanted tumors after intravenous administration of epinephrine [36, 37].  Using similar 
technique, however Rockoff [68] concluded that the response to epinephrine is highly tumor 
type dependent.  Evidently, as in the "hard" tumor type in Table 2, there was some capacity 
for vasoconstriction in these tumors, so that when epinephrine was injected selectively into 
the tumor circulation, tumor flow decreased. Further, hydralazine actually increased tumor 
perfusion somewhat for this type of tumor.  
 
Most such observations can be reconciled with known anatomic differences among tumor 
types by a modest addition to the parallel simple parallel circuit model, shown in Figure 6, in 
which the tumor resistance, R2, is represented as the series (in-line) combination of active 
elements, R2a, and fixed, inactive elements, R2b.  The active resistance element, R2a, represents 
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the resistance of tumor feeder vessels, able to constrict and dilate. The remainder of tumor 
resistance, R2b is assumed to be comprised of non-responsive vessels that do not dilate or 
constrict.  If tumor feeder vessels are maximally dilated initially and a vasodilator drug is 
given, then their resistance can be included with the fixed tumor resistance, R2b, for the 
purpose of analysis, and the network would behave essentially as the parallel circuit in Figure 
6. If tumor feeder vessels are able to react to some degree as normal vessels do when a 
vasoconstrictor drug is given, then they are best represented as R2a + R2b, and the effect of the 
variable resistance, R2a, must be taken into account. 
 
The existence of such active tumor feeder vessels can explain subtle variations in the data in 
Figure 5 and Table 2 from reference [14]. In that study the amount of vascular smooth muscle 
seen microscopically in the "soft tumor" was essentially zero, whereas some vascular smooth 
muscle was seen in the "hard tumor".  If the hard tumor is assumed to have some series active 
resistance vessels (R2a), i.e. some arterioles, a vasoconstrictor would decrease flow in hard 
tumor flow, as observed, more than in the soft tumor, which had little vascular smooth 
muscle.  If the feeder vessels are already vasodilated maximally, owing to local 
autoregulatory factors, then they may not respond to vasodilators as much as they do to 
vasoconstrictors.  This may have been the case for hard tumor in Table 2. 
 
A conceptual model for predicting drug effects 
 
The effect of active feeder vessels is easily modeled in a general way by the mathematical 
expressions for current flow in series-parallel networks [43].  Study of the equations 
governing flow in such networks can aid in understanding various experimental results and 
the potentials and limitations of altering temperature distributions with vasoactive drugs.  
Suppose that i1 represents the normal tissue flow through resistance R1 and that i2 represents 
the tumor flow through series resistance R2a plus R2b.  We seek to determine the influence of a 
change in the resistance of the active vessels, designated R1 and R2a, upon the tumor / normal 
blood flow ratio, i2/i1, what Song has termed the blood flow ratio, BFR [71]. In the present 
model, BFR = i2/ 1. 
 
For the simple parallel circuit model in Figure 6, the BFR = R1/R2. When the series resistance 
of active feeder vessels is separately accounted for as R2a, the expression for BFR becomes 
R1/(R2a+R2b).  The effects of vasoactive drugs can now be modeled easily by asking the 
question: what is the percentage change in BFR produced by a given percentage change in the 
active vascular elements, R1 and R2a?  Since feeder vessels, R2a, behave similarly to normal 
vessels, R1, then we can represent R2a = kR1 for some arbitrary constant, k, during 
vasoconstricion or vasodilation.  In this case the resistance of active feeder vessels remains 
proportional to that of normal vessels in response to vasoconstricting and vasodilating stimuli.  
Substituting for R2a, and differentiating with respect to R1, we find that the change in tumor 




and the relative change in BFR, 





This last expression is quite revealing.  It states that the percentage change in BFR is 
determined by two factors: the extent to which tumor feeder vessels are inactive, represented 








If tumor resistance vessels are completely unresponsive then R2a = 0 and this term equals 
unity.  In this case the percentage change in BFR is equal to the percentage change in normal 
vascular resistance, the maximal possible effect.  However, if R2a >> R2b, that is most of the 
resistance vessels of the tumor are normally vasoactive, then the change in the tumor blood 
flow ratio approaches zero in the face of vasodilation. 
 
The other term in the expression for the fractional change in tumor blood flow, (BFR) / BFR 
is the relative change in normal tissue vascular resistance.  If the vascular resistance in 
surrounding normal tissue is high to begin with, and subject to a large effect of vasoactive 
drug, then the influence of vasodilators upon the blood flow ratio will be correspondingly 
high.  This appears to be the case for dog hind limb (Figure 7).  Skin and muscle normally 
have high vascular resistance and low blood flow, but are capable of substantial vasodilation, 
as is evident in normal exercise.  Thus, if the tumor is in parallel with a normally high 
vascular resistance, R1, such as the skeletal muscle or skin, then the change in the blood flow 
ratio will be large.  This mathematical analysis would suggest that vasodilator drugs may be 
effective adjuncts to local hyperthermia for tumors that tend to have little vascular smooth 
muscle and are located in pre-existing normal vascular beds capable of substantial 
vasodilation.  The effect of vasodilators may be less in central tumors, surrounded by well 
perfused tissues.  The complexities introduced by differences in tumor vascular histology, 
which can be easily studied in autopsy material, and differences in tumor location and 
vascular perfusion, which can be easily studied in animal models, upon the potential drug 
induced changes in BFR are deserving of much further investigation. 
 





Figure 7. Effects of hydralazine on tumor vs. normal tissue blood flow in dogs. Mean 
blood flow for tumor and underlying normal muscle obtained during four different test 
conditions: normothermic, no drug (Trial 1); hyperthermic, no drug (Trial 2); 
normothermic, hydralazine (Trial 3); and hyperthermic, hydralazine (Trial 4).  
Data from Voorhees and Babbs, 1982. 
 
 
Potential for practical enhancement of hyperthermia therapy 
 
If circulatory dysfunction of the primitive and over extended microvasculature of tumors 
could be maximized by vasoactive agents, selective hyperthermic treatment of tumors might 
be greatly facilitated.  Specifically, pretreatment of a patient with a direct-acting vasodilator 
d1ug would be expected to lower vascular resistance in normal tissues, increasing perfusion in 
them, while simultaneously shunting blood flow away from the tumor--provided that 
surrounding normal tissues (R1) have a good capacity for vasodilation.  As previously 
reviewed, such effects have, in fact, been described in experimental animals, for the 
vasodilators isoproterenol, chlorpromazine, amyl nitrite [54, 55], hydralazine, and 
prostaglandin E2 [64].  Much of the literature concerning the effect of vasoactive drugs upon 
tumor blood flow has been well reviewed by Jain and Ward-Hartley [47]. 
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Our own work at Purdue has also demonstrated this effect.  Results of computer modeling 
showing the effects of tumor size upon temperature distributions (Figure 1) led us to 
investigate a larger animal model: the transmissible venereal tumor (TVT) in dogs. The 
biology and natural course of the TVT have been well described [18-20, 30, 67].  In brief, the 
TVT is a naturally occurring neoplasm of the penis and vagina of dogs. Transmission from 
animal to animal occurs during coitus.  The TVT is a relatively rapidly growing sarcoma.  It 
often undergoes spontaneous regression and appears to be highly immunogenic.  For these 
reasons it is ill suited to studies in which tumor regression is the endpoint.  However, it can be 
used a model for effects upon tumor physiology and blood flow. Experimentally, the tumors 
can be seeded in young, unaffected animals by hypodermic injection of TVT cell suspensions 
and will grow in locations where they would not often occur in nature to create tumor nodules 
weighing 50 to 100 grams. 
 
We initiated TVTs in the subcutaneous tissue of the hindlimbs in dogs, using the technique of 
Epstein [30] and Cohen [19].  After a growing period of 40 to 80 days, subcutaneous 
transmissible venereal tumor implants were heated by inductive diathermy using Helmholtz 
coils in 8 dogs. The temperature rise in tumor and adjacent muscle was measured before and 
after giving hydralazine (0.5 mg/kg i.v.).  Blood flow to the tumors and underlying muscle 
was measured with radioactive tracer microspheres (Figure 7). Before hydralazine treatment, 
mean muscle blood flow was about one-third tumor blood flow (0.11  0.02 vs. 0.28 ± 0.09 
ml/min/g).  During radiofrequency heating tumor and normal muscle temperatures were not 
significantly different (40.0  0.6 vs. 39.7  0.1 °C).  After hydralazine, tumor blood flow 
decreased and muscle blood flow increased in every dog. Muscle blood flow increased to 0.67 
 0.13 ml/min/g, 17 times tumor blood flow, which decreased to 0.04  0.02 ml/min/g, and 
selective heating of the tumors was easily achieved.  
 
The complete temperature-time curves for a typical experiment are shown in Figure 8. In 
general, when the temperature of the normal tissue was raised to a steady-state target level of 
approximately 40 °C before giving hydralazine, the temperature measured in the tumor was 
never more than 42.2 °C and never more than 2.5 °C higher than normal tissue temperature.  
In 4 of the 8 dogs it was impossible to raise the temperature of the tumor to a level higher than 
the normal tissue before hydralazine treatment.  When, after the injection of hydralazine, the 
temperature of the normal tissue was again raised to a target level of about 40 °C, tumor 
temperature rose as high as 51.6 °C. In every animal, hydralazine treatment permitted 
dramatic selective heating of the tumor at doses that did not depress blood pressure 
unacceptably.  Although the drug decreased peripheral resistance by about one-half, blood 
pressure was maintained at reasonable levels (80 mmHg mean) by the reactive increase in 
cardiac output. 





Figure 8. Temperature-time curves before and after hydralazine for tumor and 
underlying normal muscle. Data from Voorhees and Babbs, 1982. 
 
 
In another preliminary study of the canine venereal tumor Nussbaum and coworkers [61] 
found that intravenous administration of hydralazine to a mongrel dog with a transplanted, 
superficial tumor nodule in the abdomen increased temperature differences between tumor 
and adjacent normal tissues by 2 °C during interstitial hyperthermia therapy with coaxial 
microwave antennas.  Concomitant changes in blood flow, determined with positron emission 
tomography (PET scanning) suggested that a significant decrease in tumor perfusion was 
produced by the drug. 
 
The forgoing studies in the canine transmissible venereal tumor model used hydralazine doses 
of 0.5 mg/kg, i.v. This dose could be potentially hazardous in normotensive patients, because 
of risks of postural hypotension following the treatment.  However, subsequent studies by 
Roemer et al. [69] in normal dogs indicated that local changes in blood flow during 
hyperthermia could occur following doses as low as 0.125 mg/kg.  Dewhirst and coworkers 
(International Journal of Hyperthermia 6(6), 971-983) have conducted a coordinated study of 
human subjects having chest wall or neck tumors treated with microwave hyperthermia 
delivered by spiral microstrip antennas.  They found increased temperature in 10 of 14 
patients from 1 to 34 minutes after administration of this low dose of hydralazine.  Tumor 
temperature decreased in one patient and was unchanged in three.  Mean arterial blood 
pressure decreased in the range of from 0 to 20 mmHg maximally. Dewhirst and coworkers 
advocated further exploration of shorter acting and more controllable vasodilator drugs, such 
as intravenous sodium nitroprusside, to minimize complications of post-procedural 
hypotension. 
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Selection of the most effective vasodilatory agent and dose will require continued careful 
investigation and may well be species dependent.  For example, Horsman and coworkers [42] 
used single intravenous doses of hydralazine to enhance hyperthermic damage to C3H 
mammary tumor implants in mice.  They found maximal benefit at 2.5 mg/kg, 1 hour after 
drug injection, and documented prolonged hypotension lasting 6 to 8 hours.  This time course 
of action is much longer than needed in most practical hyperthermia treatments, again 
suggesting that shorter acting vasoactive agents are worthy of investigation. 
 
Further sophistication is also needed with respect to the anatomic location of neoplastic 
lesions treated with heat in conjunction with vasodilators.  The influence of drugs like 
hydralazine may be especially effective for tumors implanted in an extremity, where resting 
vascular resistance of surrounding skin and skeletal muscle is high.  The normal renal 
vascular bed is exquisitely sensitive to hydralazine and other vasodilators but the cerebral 
vascular bed is not [16]. Hence one can reasonably expect that the local vascular steal 
phenomenon would be greater for renal than for cerebral tumors.  Nevertheless, even though 
the ideal agents, dosage regimens, and clinical indications have yet been identified, the 
preponderance of evidence currently available suggests that adjuvant treatment with 
vasodilators of some sort may well be a feasible technique to increase temperature differences 




Effective local heat therapy for cancer requires selective elevation of intratumoral temperature 
without overheating of surrounding normal tissues. For larger tissue volumes the major 
factors that determine local temperature elevation are absorbed power density, which heats the 
treated tissue, and blood pe1fusion, which cools it. Selectivity can thus be achieved either by 
technology able to focus thermal energy directly within tumor tissues or by manipulations of 
vascular physiology to increase blood cooling of normal tissues or decrease blood cooling of 
tumor tissue. This review has focused on the therapeutic advantage related to spontaneous or 
induced differences in blood flow. 
 
Solutions of the bio-heat transfer equation predict that selective elevation of tumor 
temperature is quite sensitive to changes in the normal / tumor blood flow ratio.  Greater flow 
in normal tissue and/or less flow in tumor tissue permits selective elevation of intratumoral 
temperatures, even without focusing of absorbed power within the tumor.  The effects of 
differential perfusion are further multiplied if arterial blood temperature is reduced by 
systemic cooling. 
 
A favorable normal/tumor blood flow ratio is the rule because the small blood vessels 
supplying most tumors are anatomically quite different from the microvasculature of normal 
tissues. Tumor circulation is a weak link in the logistical organization of tumor tissue, and it 
may be possible to exploit this weakness in cancer therapy [65].  In particular, the structural 
differences between tumor and normal vessels provide the anatomic substrate for differing 
vascular responses, both to heat and to vasoactive drugs. Normal arterioles dilate in heated 
tissues to raise local blood flow; tumor vessels generally do not. The enhanced blood cooling 
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of normal tissues under heat stress provides an explanation for the relatively greater 
destructive effect of heat upon tumor vs. normal cells in vivo than in vitro. 
 
The differences in vascular response also provide a target for selective drug action that can be 
exploited to enhance local heat therapy of tumors.  Vasodilators, in particular, have profound 
effects upon the distribution of blood flow between tumor and adjacent normal tissues. 
Dilation of normal arterioles improves blood flow in normal tissues and may also shunt blood 
away from the tumor.  In the presence of vasodilator drug, steady-state tumor temperatures of 
45-50 °C were achieved in one large animal tumor model in response to increased power 
input, while surrounding normal tissues remained below 42 °C. Quite possibly, vasoactive 
drugs, which either constrict or dilate arterioles, can be used to alter the distribution of blood 
flow between tumor and normal tissues to therapeutic advantage. 
 
The effects of vasoactive drugs on the tumor/normal blood flow ratio are relatively 
non-controversial and consistent.  They are demonstrable in small animals, large animals, and 
humans to varying degrees.  In clinical pharmacoangiography, vasoactive drugs have been 
employed for amplifying the radiographic contrast between normal and cancerous [1, 9, 49, 
51, 68].  In radiation therapy such drugs have been investigated in hopes of increasing the 
oxygen tension within tumors during treatments [3, 37, 39, 54, 55].  In chemotherapy, such 
drugs may help by preferentially channeling cytotoxic drugs into the tumor tissue [54]. Thus, 
the application of vasoactive drugs in hyperthermia represents a logical extension of earlier 
work. 
 
There is still much to be learned, however, and there are some complexities of circulatory 
physiology to be mastered.  Translation of preclinical, animal data to viable procedure in 
human medicine remains a formidable challenge.  Selection of the optimal vasoactive agents 
and their doses remains a challenge.  Specific clinical indications have yet to be established.  
Because powerful, systemically acting drugs are involved, an interdisciplinary approach, 
involving both medical and radiation oncologists will be the most likely to succeed. The 
outlook for the development of a useful new adjunct to hyperthermia therapy, however, is 
bright.  Further clinical exploitation of the microvascular differences between tumors and 
adjacent normal tissues would seem to provide a major opportunity for future research and 
patient benefit. 
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